Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-01-18
2004-08-24
Seidel, Marianne C. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S343000, C514S214030, C514S226200
Reexamination Certificate
active
06780871
ABSTRACT:
FIELD OF THE INVENTION
The present application relates, generally, to methods of treating addiction disorders using &agr;
3
&bgr;
4
nicotinic receptor antagonists and to compositions useful in such treatments.
BACKGROUND OF THE INVENTION
Drug and alcohol addiction and/or abuse and/or dependency (collectively referred to herein as “addiction disorders”) is extremely common. Individuals suffering from such addictions are generally subject to significant symptoms of withdrawal upon attempting to cease use of the addictive substance (whether alcohol or drugs such as cocaine, heroine, nicotine, painkillers, etc.). A number of medical therapies have been tried with differing levels of success. Unfortunately, to date, none of these methods of treatment have been very successful. For this and other reasons, a need exists for improved methods for treating addictive disorders.
SUMMARY OF THE INVENTION
The present invention relates to a method for treating an addiction disorder in a patient. The method includes administering to the patient a first &agr;
3
&bgr;
4
nicotinic receptor antagonist and administering to the patient a second &agr;
3
&bgr;
4
nicotinic receptor antagonist. The second &agr;
3
&bgr;
4
nicotinic receptor antagonist is different than the first &agr;
3
&bgr;
4
nicotinic receptor antagonist, and the first &agr;
3
&bgr;
4
nicotinic receptor antagonist and the second &agr;
3
&bgr;
4
nicotinic receptor antagonist are administered simultaneously or non-simultaneously.
The present invention also relates to a composition which includes a first &agr;
3
&bgr;
4
nicotinic receptor antagonist and a second &agr;
3
&bgr;
4
nicotinic receptor antagonist. In this composition, the second &agr;
3
&bgr;
4
nicotinic receptor antagonist is different than the first &agr;
3
&bgr;
4
nicotinic receptor antagonist.
The present invention also relates to a composition which includes a first compound selected from the group consisting of mecamylamine, 18-methoxycoronaridine, bupropion, dextromethorphan, dextrorphan, and phamaceutically acceptable salts and solvates thereof; and a second &agr;
3
&bgr;
4
compound selected from the group consisting of mecamylamine, 18-methoxycoronaridine, bupropion, dextromethorphan, dextrorphan, and phamaceutically acceptable salts and solvates thereof. In this composition, the second compound is different than the first compound.
The present invention also relates to a method of evaluating a compound for its effectiveness in treating addiction disorders by assessing the compound's ability to bind to &agr;
3
&bgr;
4
nicotinic receptors.
The present invention also relates to a method for treating an addiction disorder in a patient. The method includes administering to the patient an &agr;
3
&bgr;
4
nicotinic receptor antagonist under conditions effective to treat the patient's addiction disorder.
REFERENCES:
patent: 5654281 (1997-08-01), Mayer et al.
patent: 5863927 (1999-01-01), Smith et al.
patent: 5965567 (1999-10-01), Archer et al.
patent: 6211360 (2001-04-01), Glick et al.
patent: WO 99/17803 (1999-04-01), None
Murray et al., “Interaction of Dextrorotary Opioids with Phencyclidine Recognition Sites in Rat Brain Membranes,”Life Sci., 34:1899-1911 (1984).
Nishikawa et al., “Evidence for, and Nature of, the Tonic Inhibitory Influence of Habenulointerpeduncular Pathways upon Cerebral Dopaminergic Transmission in the Rat,”Brain Res., 373:324-336 (1986).
Koyuncuoglu et al., “The Treatment of Heroin Addicts with Dextromethorphan: A Double-blind Comparison of Dextromethrophan with Chlorpromazine,”Int. J. Clin. Pharmacol. Ther., 28:147-152 (1990).
Glick et al., “Effects and Aftereffects of Ibogaine on Morphine Self-administration in Rats,”Europ. J. Pharmacol., 195:341-345 (1991).
Flores et al., “A Subtype of Nicotinic Cholinergic Receptor in Rat Brain Is Comprised of 4 and 2 Subunits and Is Up-regulated by Chronic Nicotine Treatment,”Mol. Pharmacol., 41:31-37 (1992).
Koyuncuoglu, “The Combination of Tizanidine Markedly Improves the Treatment with Dextromethorphan of Heroin Addicted Outpatients,”Int. J. Clin. Pharmacol. Ther., 33:13-19 (1995).
Popik et al., “NMDA Antagonist Properties of the Putative Antiaddictive Drug, Ibogaine,”J. Pharmacol. Exp. Ther., 275-753-760 (1995).
Sweetnam et al., “Receptor Binding Profile Siggest Multiple Mechanisms of Action Are Responsible for Ibogaine's Putative Anti-addictive Activity,”Psychopharmacology, 118:369-376 (1995).
Chen et al., “Ibogaine Block of the Nmda Receptor: in Vitro and in Vivo Studies,”Neuropharmacology, 35:423-431 (1996).
Glick et al., “18-Methoxycoronaridine, a Non-toxic Iboga Alkaloid Congener: Effects of Morphine and Cocaine Self-administration and on Mesolimbic Dopamine Release in Rats,”Brain Res., 719:29-35 (1996).
Badio et al., “Ibagaine: A Potent Noncompetitive Blocker of Ganglionic/Neuronal Nicotinic Receptors,”Molec. Pharmacol., 51:1-5 (1997).
Pulvirenti et al., “Dextromethorphan Reduces Intravenous Cocaine Self-administration in the Rat,”Eur. J. Pharmacol., 321:279-283 (1997).
Rezvani et al., “Attenuation of Alcohol Consumption by a Novel Non-toxic Ibogaine Analog (18-Methoxycoronaridine) in Alcohol Preferring Rats,”Pharmacol. Biochem. Behav., 58:615-619 (1997).
Ebert et al., “Opioid Analgesics as Noncompetitive N-methyl-d-aspartate (NMDA) Antagonists,”Biochem. Pharmacol., 56:533-559 (1998).
Glick et al., “Mechanisms of Anti-addictive Actions of Ibogaine,”Ann. N.Y. Acad. Sci., 844, 214-226 (1998).
Mah et al., “Ibogaine Acts at the Nicotinic Acetylcholine Receptor to Inhibit Catecholamine Release,”Brain Res., 797:173-180 (1998).
Fryer et al., “Noncompetitive Functional Inhibition at Diverse , Human Nicotinic Acetylcholine Receptor Subtypes by Bupropion, Phencyclidine, and Ibogaine,”J. Pharmacol. Exp. Ther., 288:88-92 (1999).
Lukas et al., “International Union of Pharmacology, XX, Current Status of the Nomenclature for Nicotinic Acetylcholine Receptors and Their Subunits,”Pharmacol. Rev., 51:397-401 (1999).
Maisonneuve et al., “Attenuation of the Reinforcing Efficacy of Morphine by 18-Methoxycoronaridine,”Euro. J. Pharmacol., 383:15-21 (1999).
Quick et al., “3 4 Subunit-containing Nicotinic Receptors Dominate Function in Rat Medial Habenula Neurons,”Neuropharmacology, 38:769-783 (1999).
Reid et al., “A Nicotinic Antagonist, Mecamylamine, Reduces Cue-induced Craving in Cocaine-dependent Subjects,”Neuropsychopharmacology, 20:297-307 (1999).
Glick et al., “18-MC Reduces Methamphetamine and Nicotine Self-Administration in Rats,”NeuroReport, 11:2013-2015 (2000).
Glick et al., “18-Methoxycoronaridine (18-MC) and Ibogaine: Comparison of Anti-addictive Efficacy, Toxicity and Mechanisms of Action,”Ann. N.Y. Acad. Sci., 914:369-387 (2000).
Glick et al., “Development of Novel Medication for Drug Addicition: The Legacy of an African Shrub,”Ann. N.Y. Acad. Sci., 909:88-103 (2000).
Hernandez et al., “Dextromethorphan and its Metabolite Dextrorphan Block 3 4 Neuronal Nicotinic Receptors,”J. Pharmacol. Exp. Ther., 293:962-967 (2000).
Jun et al., “Dextromethorphan Alters Methamphetamine Self-Administration in the Rat,”Pharmacol. Biochem. Behav., 67:405-409 (2000).
Levin et al., “Mecamylamine Preferentially Inhibits Cocaine Versus Food Self-administration in Rats,”Soc. Neurosci. Abstr., 26:1821 (2000).
Glick et al., “Comparative Effects of Dextromethorphan and Dextrorphan on Morphine, Methamphetamine, and Nicotine Self-administration in Rats,”Europ. J. Pharmacol., 422:87-90 (2001).
Klink et al., “Molecular and Physiological Diversity of Nicotinic Acetylcholine Receptors in the Midbrain Dopaminergic Nuclei, ”J. Neurosci., 21:1452-1463 (2001).
Papke et al., “Analysis of Mecamylamine Steroisomers on Human Nicotinic Receptor Subtypes,”J. Pharmacol. Exp. Ther., 297:646-656 (2001).
Glick Stanley D.
Maisonneuve Isabelle M.
Albany Medical College
Kwon Brian-Yong S.
Rogalskyj & Weyand LLP
Seidel Marianne C.
LandOfFree
Methods and compositions for treating addiction disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for treating addiction disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for treating addiction disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3355127